A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona biopsją lub badaniem cytologicznym adenokarcinoma trzustki
- •Nowotwór zaawansowany lokalnie lub niemożliwy do usunięcia chirurgicznie, oceniony przez zespół specjalistów
- •Brak przerzutów do innych narządów
- •Ukończone uprzednio chemioterapię pierwszego rzutu
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia, umożliwiający tolerowanie radioterapii
- •Zdolność do współpracy przy procedurach radioterapii, w tym technikach wstrzymania oddechu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
City of Hope
Duarte, United States
CIty of Hope
Irvine, United States
Karmanos Cancer Institute
Detroit, United States
Christus St. Vincent Regional Cancer Center
Santa Fe, United States
Oncology Consultants, P.A.
Houston, United States
Trial contact
Robbin Frnka
Jeanne Jones
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.